1. Introduction
Influenza virus continues to pose a significant global health threat and is one of the leading causes of seasonal respiratory infections. Vaccination remains the primary intervention strategy to mitigate influenza-related morbidity, hospitalization, and mortality, particularly among the elderly and individuals with chronic diseases [
1]. Despite strong recommendations from the World Health Organization for annual influenza vaccination of high-risk groups, global coverage rates remain suboptimal, especially in low- and middle-income countries [
2,
3]. A major barrier to broader vaccine uptake is the reliance on conventional intramuscular delivery route, which is invasive, often poorly accepted by recipients, and requires trained personnel and disposable medical supplies. These challenges are further compounded in resource-limited settings, where shortages of personnel, infrastructure, and logistical capacity constrain large-scale immunization efforts [
4].
To address these limitations, needle-free vaccination strategies are actively being explored. Among them, oral immunization through the gastrointestinal tract offers a non-invasive, user-friendly alternative that reduces logistical complexity and healthcare expenditure [
5]. Preclinical studies have demonstrated that oral administration of inactivated influenza antigen can induce both systemic immune responses and mucosal immune responses. However, antigen degradation by gastric acid, digestive enzymes, and bile salts, substantially reduces bioavailability, thereby limiting immunogenicity [
5,
6]. This inherent limitation underscores the need for novel delivery strategies that can preserve antigen structure or bypass gastrointestinal transit altogether.
Orally dissolving films (ODFs) have emerged as a promising alternative to conventional oral delivery system, offering both structural advantages and immunological advantages over the conventional influenza vaccines. These solid-state formulations, composed of biocompatible film-forming agents, effectively maintain the structural integrity and bioactivity of embedded substances by minimizing degradation and enhancing stability under variable environmental conditions [
7]. ODFs dissolve rapidly upon contact with saliva, eliminating the need for water intake and thereby enhancing user convenience and improving compliance, especially in individuals with swallowing difficulties [
8]. Their flexible film format also enables easy dose customization and simplifies storage and transportation [
9].
Beyond these structural advantages, ODFs enable direct antigen delivery to the oral mucosa, bypassing the harsh gastrointestinal environment and hepatic first-pass metabolism. This localized delivery enhances antigen stability and exposure at mucosal inductive sites, which may lead to improved immunogenicity [
9]. In our previous work, we incorporated inactivated influenza antigens into a pullulan–trehalose-based ODF matrix. This formulation elicited robust immune responses and conferred complete protection against lethal influenza virus challenge in animal models, with preliminary evidence of a dose-sparing effect [
10,
11]. However, a direct comparison between ODF vaccination and conventional oral administration has not yet been conducted. Building on these prior findings, the present study employed a murine model to compare the immunogenicity and protective efficacy of ODF-based vaccines versus orogastric vaccine delivery. This investigation aimed to further evaluate the translational potential of ODFs as a practical, recipient-friendly alternative for influenza vaccine administration.
2. Materials and Methods
2.1. Ethics Statement
Animal experimental schedule was conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health) and was approved by the Institutional Animal Care and Use Committee of Kyung Hee University (accession number: KHUASP-SE-18-024). Mice were housed in a specific pathogen-free facility with a controlled environment (22 ± 2 °C, 50 ± 10% humidity, and 12 h light/dark cycle) and were given ad libitum access to chow and water. All efforts were made to minimize suffering. Prior to all invasive procedures, mice were anesthetized using inhaled isoflurane. Mice exhibiting signs of severe distress, reaching a humane intervention point defined as a loss of more than 25% of initial body weight, or those at the end of the study, were humanely euthanized via CO2 inhalation followed by cervical dislocation.
2.2. Cell Maintenance and Virus Preparation
Madin-Darby Canine Kidney (MDCK) cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Welgene, Gyeongsan, South Korea) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (p/s) and maintained at 37 °C in a humidified incubator with 5% CO
2. Influenza A/Puerto Rico/8/1934 (H1N1, PR8) virus was propagated in an 11-day-old SPF embryonated chicken eggs as previously described [
11]. Diluted virus stock was injected into the allantoic cavity and the eggs were incubated at 37 °C for 2.5 days. Following incubation, the eggs were chilled at 4 °C for 12 h. Allantoic fluid was then collected and clarified by centrifugation at 4750 rpm for 30 min at 4 °C. The harvested supernatants were either used directly for animal challenge experiments or subjected to formalin inactivation. Inactivated PR8 virus particles were purified using a 60%/30%/15% sucrose density gradient and were subsequently used as coating or stimulating antigens in immunological assays, as well as a component of the ODF vaccines.
2.3. Formulation of ODF Vaccines
ODF vaccines were prepared as previously described with minor optimizations [
10,
11]. Briefly, pullulan (Tokyo Chemical Industry, Tokyo, Japan) and trehalose (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in distilled water to form the film-forming matrix. Each formulation contained 12 μg of pullulan and 3 μg of trehalose per 20 μL of solution. Inactivated PR8 virus was added to the solution at a final dose of 100 μg to generate a homogeneous liquid vaccine formulation. For control films, 100 μg of bovine serum albumin (BSA) was incorporated instead of PR8. The vaccine solution was cast onto a parafilm surface in 3 mm × 3 mm squares and air-dried at room temperature for 4 h in a Class II biosafety laminar flow cabinet. The resulting solid ODF vaccines were detached, characterized by measurements of thickness, weight, and HA titer before use in immunization experiments.
2.4. Hemagglutination (HA) Assay
The functional integrity of the antigen incorporated into the ODF vaccines was evaluated using a standard HA assay [
11]. Antigen samples, including the inactivated PR8 virus in liquid formulation and reconstituted ODF vaccines, were diluted 1:100 in phosphate-buffered saline (PBS). A volume of 50 μL aliquot of each diluted sample was added to the first column of a U-bottom 96-well microtiter plate, followed by serial two-fold dilutions across the plate. Then, 50 μL of the 0.5% chicken RBC (cRBC) suspension was added to each well, and plate was incubated at room temperature for 1 h. HA titers were determined as the highest dilution factor at which complete hemagglutination was observed. Titers were expressed as log
2 values. Negative controls included PBS and blank film formulations containing only pullulan and trehalose. An equivalent amount of inactivated PR8 virus without any ODF components was used as the positive control.
2.5. Immunization and Challenge
Thirty-two female BALB/c mice (SPF, 7 weeks old, 18–20 g) were purchased from Nara Biotech (Seoul, South Korea). Each individual mouse was considered an experimental unit. Following one week of acclimation, mice were randomly assigned to two experimental groups (ODFV and Oral; n = 8 per group) and two control groups (Naive and Naive + Challenge; n = 8 per group). The total sample size was determined based on prior literature involving preclinical vaccine studies [
10,
11]. Experimental groups were immunized with inactivated influenza PR8 virus, either via oral gavage (diluted in 100 μL PBS) or using the ODF platform. For ODF administration, a single vaccine film was placed on the tongue of mice and held in place until complete dissolution [
10,
11]. All groups received three immunizations at four-week intervals, with each dose containing an equivalent antigen amount (50 μg). Naive group received PBS alone, while the Naive + Challenge group served as an unimmunized infection control. Peripheral blood was collected one week after each immunization to evaluate systemic antibody responses, and an additional blood sample was obtained two weeks after the final dose to assess hemagglutination inhibition (HAI) and virus-neutralizing activities. At four weeks after the final immunization, all groups except the naive control were intranasally challenged with 5 × LD
50 of live PR8 virus in a 50 μL volume. At 4 days post-infection (dpi), four mice from each group were randomly selected and euthanized for the collection of tissues used in immunological and virological analyses. The remaining mice were monitored for 14 days post-challenge to assess daily body weight changes and survival outcomes.
All mice were housed and handled under standardized conditions to minimize environmental variability. Immunizations, viral challenges, and sample collections were conducted simultaneously across all groups, with treatments administered in a random order to reduce procedural bias. While cage location and handling order were not systematically varied, all procedures were performed according to consistent protocols to limit potential confounding factors. No priori inclusion or exclusion criteria were defined. All animals enrolled in the study completed the full immunization and challenge schedule, and no experimental units or data points were excluded from the analysis. All collected samples met quality control standards and were included in the final dataset.
2.6. Sample Collection and Processing
Blood samples were collected via retro-orbital plexus puncture after each immunization. Samples were centrifuged at 6000 rpm for 10 min to isolate serum, which was used to assess antibody responses and functional analyses. At 4 dpi, mice were euthanized, and mucosal samples were collected by flushing the trachea. Lung tissues were homogenized in PBS, filtered through a 100 μm cell strainer, and centrifuged at 2000 rpm for 10 min. Supernatants were collected for subsequent pro-inflammatory cytokine and viral burden analyses. Cell pellets were washed and resuspended in diluted Percoll for density gradient centrifugation to isolate lung lymphocytes. Cell pellets from spleens were collected using the same procedure and treated with RBC lysis buffer. Final single cell suspensions from lung and spleen samples were used for antibody-secreting cell (ASC) assays and flow cytometric analysis of immune cell populations. Group allocation was known to the investigators throughout sample collection and subsequent analyses, and blinding was not applied.
2.7. Virus-Specific Antibody Response Measurement
PR8 virus-specific IgG and IgA antibody responses in serum and mucosal samples were quantified using an enzyme-linked immunosorbent assay (ELISA) [
12]. Briefly, 96-well immunoplates were coated with 5 μg/mL of inactivated PR8 virus diluted in carbonate-bicarbonate coating buffer (pH 9.6). After coating, plates were washed three times with PBS containing 0.05% Tween-20 (PBST) and blocked with 0.2% gelatin in PBST for 2 h at 37 °C. Samples were serially diluted in PBS and added to the plates, followed by incubation at 37 °C for 1 h. After washing with PBST, bound antibodies were detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG or IgA in 1:2000 dilution for 1 h incubation at 37 °C. Color development was achieved using citrate–phosphate buffer containing o-phenylenediamine (OPD and H
2O
2). Optical density was measured at 450 nm using a microplate reader (Biochrom Ltd., Cambridge, UK).
2.8. HAI and Virus Neutralization Assays
To evaluate functional antibody responses against influenza virus, HAI and virus neutralization assay were conducted as previously described [
10]. Briefly, sera were treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan) according to the manufacturer’s instructions. For HAI assay, treated sera was serially diluted and mixed with 4 HAU of PR8 virus suspension, followed by incubation for 30 min at room temperature. Following incubation, 0.5% cRBCs were added to each well and incubated for an additional hour. The HAI titer was defined as the reciprocal of the highest serum dilution that completely inhibited HA. Virus neutralization was determined using a plaque reduction assay. Serially diluted sera were mixed with 100 plaque-forming units (PFU) of live PR8 virus and incubated at 37 °C for 1 h to allow neutralization. The serum-virus mixtures were then added to confluent MDCK cell monolayers and adsorbed for 1 h at 37 °C with 5% CO
2. After removing the infection inoculum, cells were overlaid with medium supplemented with 2× DMEM, DEAE-dextran, MEM NEAA, p/s, glutamine, and trypsin. Plates were incubated at 37 °C for 4 days, after which cells were fixed with 4% paraformaldehyde for 30 min and stained with 1% crystal violet to visualize plaques. The number of plaques in each well was counted, and the percentage of neutralization was calculated relative to the plaque number in wells without serum treatment.
2.9. ASC Response Evaluation
Single-cell suspensions from lungs and spleens were counted using hemocytometers and seeded at a density of 1 × 10
6 cells per well into 96-well flat-bottom plates pre-coated with inactivated PR8 virus antigen (5 μg/mL). Cells were cultured at 37 °C in a 5% CO
2 incubator for 5 days. To detect PR8-specific ASCs, cell culture supernatants were removed and incubated with HRP-conjugated anti-mouse IgG (1:1000 dilution) for 1 h at 37 °C. After washing with PBST, OPD substrate solution was added to each well for color development. Absorbance was measured at 450 nm using a microplate reader (Biochrom Ltd., Cambridge, UK) [
10].
2.10. Flow Cytometry Analysis of Immune Cell Populations
Single-cell suspensions from lungs and spleens were prepared as previously described and adjusted to a concentration of 1 × 10
6 cells per 100 μL in RPMI-1640 medium (Welgene) supplemented with 10% FBS and 1% p/s [
10]. To enhance surface marker expression and antigen-specific activation, cells were stimulated with inactivated PR8 virus (5 μg/mL) for 2 h at 37 °C before FcR blocking. After 15 min of blocking, cells were stained for 30 min at 4 °C in PBS buffer containing 2% FBS and 0.1% sodium azide with fluorochrome-conjugated monoclonal antibodies purchased from BD Biosciences (San Jose, CA, USA): CD3-FITC, CD4-PE-Cy7, CD8a-PE, B220-FITC, GL7-PE, CD45-FITC, CD19-PE-Cy7, IgD-PE, and CD38-Alexa647. Flow cytometric data were acquired using an Accuri C6 flow cytometer and analyzed with C6 Accuri software (version 227.4, BD Biosciences). Lymphocytes were gated based on forward and side scatter profiles, and data were reported as the percentage of each stained population within the total lymphocytes. To calculate absolute cell numbers, the total lymphocyte count per sample was multiplied by the corresponding percentage of each gated subset.
2.11. Pro-Inflammatory Cytokine Measurement
Lung tissue homogenates were prepared from mice at 4 dpi. Concentrations of pro-inflammatory cytokines IFN-γ and IL-6 in the lung supernatants were quantified using commercial BD OptEIA™ ELISA kits (BD Biosciences), following the manufacturer’s instructions. Cytokine concentrations were calculated based on standard curves generated from recombinant cytokine standards provided with the kits.
2.12. Lung Viral Titer Determination
Viral burdens were determined by plaque assay using the supernatants from lungs collected at 4 dpi [
10]. Briefly, MDCK cells were seeded in 12-well tissue culture plates and grown to 90–100% confluence. Prior to infection, cells were washed with PBS and inoculated with 10-fold serial dilutions of lung homogenates prepared in DMEM medium. Virus adsorption was carried out for 1 h with gentle rocking every 15 min. Following adsorption, the inoculum was removed, and cells were overlaid with semisolid medium. Plates were incubated for 3–4 days at 37 °C in a 5% CO
2 incubator, fixed with 4% paraformaldehyde for 30 min, and stained with 1% crystal violet solution for plaque visualization.
2.13. Statistical Analysis
All data were analyzed using GraphPad Prism software (version 9.0, GraphPad Software, San Diego, CA, USA). Continuous variables were expressed as mean ± SD. Data normality was assessed using the Shapiro–Wilk test, and all datasets were confirmed to follow a normal distribution prior to further analysis. The significance between the groups was determined using either Student’s t-test or a one-way analysis of variance with Bonferroni’s post hoc test. Representative data from 4 individual animal experiments were provided. Statistical significance was defined as * p < 0.05, ** p < 0.01, and *** p < 0.001.
4. Discussion
Our present study systematically compared the immunogenicity and protective efficacy of a previously developed ODF vaccine with conventional oral administration route in a murine model. The ODF vaccine platform elicited significantly stronger systemic and mucosal immune responses, enhanced viral control, and more effective protection against lethal influenza challenge, supporting its feasibility and immunological advantages as a mucosal influenza vaccine.
The ODF formulation used in this study was developed through iterative optimization of earlier designs consisting of pullulan and trehalose, which allow precise antigen dosing and needle-free administration without requiring trained personnel. Our previous prototypes employed relatively large (0.8–1 cm
2) and thick (up to 350 μm) film matrices [
10,
11]. In contrast, the current formulation features a smaller (3 mm × 3 mm), thinner (~110 μm) design with a reduced casting volume of 20 μL. This optimized format enhances ease of administration, reduces storage and transportation demands, and may enhance mucosal adherence and antigen dispersion through increased surface contact during dissolution [
13,
14].
Immunologically, ODF vaccines induced earlier and more robust virus-specific IgA responses than oral delivery. IgA was detectable after a single ODF and increased with boosters, whereas oral immunization required multiple doses to elicit modest IgA responses, which remained significantly lower. This suggests that antigen delivery via the oral mucosa achieved by ODF promotes early mucosal-immune activation. This advantage may be attributed to the controlled dissolution of the solid-state matrix, enabling prolonged antigen exposure and enhancing immune cell activation [
15,
16]. Furthermore, direct absorption through the oral mucosa not only accelerates antigen uptake but also helps preserve antigen integrity by bypassing exposure to the harsh gastrointestinal conditions [
17,
18]. These features likely facilitate early IgA class switching and robust boosting of mucosal antibody responses.
Importantly, ODF vaccines elicited stronger mucosal immunity at the primary site of influenza infection, as evidenced by elevated virus-specific IgG and IgA levels in the respiratory tract. Secretory antibodies play a key role in neutralizing viruses and preventing epithelial attachment, thereby limiting viral replication [
19,
20]. This enhanced response may result from fundamental differences in antigen delivery between the two routes. Oral vaccination exposes antigens to gastric degradation, impairing immune recognition and reduces efficacy [
21,
22]. In contrast, ODF vaccines deliver intact antigens directly to the oral mucosa, thereby enhancing antigen stability, facilitating local presentation, and promoting drainage to cervical lymph nodes [
23].
These cervical nodes, though not anatomically linked to the respiratory tract, are functionally associated with respiratory immunity and may facilitate immune cell migration via mucosal cross-talk with nasal-associated lymphoid tissue [
24,
25,
26]. Consistent with this, ODF immunization resulted in significantly higher ASC and GC B cell activity in the lungs, indicating enhanced B cell activation and affinity maturation [
27]. Contrastingly, oral vaccination failed to induce comparable ASC response despite similar lung CD4
+ T cell frequencies, suggesting inefficient T–B cell interaction or a skewing of CD4
+ T cell subsets to gut-associated lymphoid tissues [
28,
29].
Cell-mediated immunity was also more effectively stimulated by ODF vaccines. Notably, only ODF vaccination induced a significant increase in CD8
+ T cells. Given the critical role of lung tissue-resident CD8
+ T cells in mediating rapid viral clearance and recovery [
30,
31], their induction likely also contributed to the lower pulmonary inflammation, reduced viral loads, and diminished tissue damage observed in the ODF group.
Despite the encouraging immunological outcomes, further investigations are warranted to fully establish the potential of the ODF platform. Evaluating its protective breadth against heterologous and heterosubtypic influenza strains will better reflect real-world applicability. In addition, long-term immune monitoring with dose sparing effects is essential to fully assess durability and practical utility of ODF-based vaccines.